KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.

Edward E Walsh, Ann R Falsey, Daniel A Scott, Alejandra Gurtman, Agnieszka M Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, David Radley, Emily Gomme, David Cooper, Beate Schmoele-Thoma

J Infect Dis 225(8) 1357-1366

PMID34932102
PMCIDPMC9016447
DOI10.1093/infdis/jiab612
发表日期2021-12-21
摘要

摘要

BACKGROUND: Protection against human respiratory syncytial virus (RSV) remains an unmet need potentially addressable by maternal immunization. This phase 1/2 study evaluated a bivalent prefusion F vaccine (RSVpreF) with antigens from RSV subgroups A and B. METHODS: Adults 18-49 years old (N = 618) were randomized to receive placebo or 60, 120, or 240 µg RSVpreF with or without Al(OH)3. Safety and immunogenicity were evaluated. RESULTS: RSVpreF recipients more frequently reported local reactions and systemic events than placebo recipients; these were mostly mild or moderate. No vaccine-related serious adverse events occurred through 12 months postvaccination. All RSVpreF formulations induced 1-month postvaccination virus-neutralizing titers higher than those associated with protection of high-risk infants by palivizumab, the only prophylactic currently available for RSV. Geometric mean fold rises (GMFRs) across RSVpreF doses/formulations were 10.6-16.9 for RSV A and 10.3-19.8 for RSV B at 1 month postvaccination, greater than those historically elicited by postfusion F vaccines. GMFRs were 3.9-5.2 and 3.7-5.1, respectively, at 12 months postvaccination. CONCLUSIONS: RSVpreF formulations were safe, well tolerated, and induced robust neutralizing responses in adults. These findings support development of RSVpreF, which is being evaluated in a pivotal phase 3 study for maternal immunization. CLINICAL TRIALS REGISTRATION: NCT03529773.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。